Pliant Therapeutics Total Debt vs. Number Of Shares Shorted

PLRX Stock  USD 13.80  0.27  2.00%   
Based on Pliant Therapeutics' profitability indicators, Pliant Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Pliant Therapeutics' ability to earn profits and add value for shareholders. At this time, Pliant Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 726.96 in 2024, despite the fact that Operating Cash Flow Sales Ratio is likely to grow to (69.96). At this time, Pliant Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Net Interest Income is likely to rise to about 20.2 M in 2024, despite the fact that Net Loss is likely to grow to (105.4 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.480.56
Fairly Down
Slightly volatile
For Pliant Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pliant Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pliant Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pliant Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pliant Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant Therapeutics. If investors know Pliant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pliant Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.35)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.28)
Return On Equity
(0.48)
The market value of Pliant Therapeutics is measured differently than its book value, which is the value of Pliant that is recorded on the company's balance sheet. Investors also form their own opinion of Pliant Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pliant Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pliant Therapeutics' market value can be influenced by many factors that don't directly affect Pliant Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pliant Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pliant Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pliant Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pliant Therapeutics Number Of Shares Shorted vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pliant Therapeutics's current stock value. Our valuation model uses many indicators to compare Pliant Therapeutics value to that of its competitors to determine the firm's financial worth.
Pliant Therapeutics is regarded second in total debt category among its peers. It is considered to be number one stock in number of shares shorted category among its peers making about  0.64  of Number Of Shares Shorted per Total Debt. The ratio of Total Debt to Number Of Shares Shorted for Pliant Therapeutics is roughly  1.56 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pliant Therapeutics' earnings, one of the primary drivers of an investment's value.

Pliant Total Debt vs. Competition

Pliant Therapeutics is regarded second in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 225.96 Million. Pliant Therapeutics holds roughly 11.37 Million in total debt claiming about 5% of equities under Health Care industry.
Total debt  Valuation  Revenue  Workforce  Capitalization

Pliant Number Of Shares Shorted vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Pliant Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
11.37 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Pliant Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
7.29 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Pliant Number Of Shares Shorted Comparison

Pliant Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Pliant Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pliant Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pliant Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Pliant Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Pliant Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income345 K362.2 K
Net Loss-111 M-105.4 M
Net Interest Income19.2 M20.2 M
Interest Income20.5 M21.5 M
Operating Income-184.1 M-174.9 M
Net Loss-155.3 M-147.5 M
Income Before Tax-161.3 M-153.3 M
Total Other Income Expense Net22.8 M23.9 M
Net Loss-161.3 M-153.3 M
Income Tax Expense1.7 M1.8 M
Non Operating Income Net Other4.5 M4.7 M
Change To Netincome26 M27.3 M
Net Loss(2.75)(2.88)
Income Quality 0.72  0.69 
Net Income Per E B T 0.89  0.59 

Pliant Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pliant Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pliant Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pliant Therapeutics' important profitability drivers and their relationship over time.

Use Pliant Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pliant Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pliant Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Pliant Therapeutics Pair Trading

Pliant Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Pliant Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pliant Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pliant Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pliant Therapeutics to buy it.
The correlation of Pliant Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pliant Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pliant Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pliant Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pliant Therapeutics position

In addition to having Pliant Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.